| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Regular Articles |
Department of Pharmaceutical Sciences, Molecular and Cellular Biology Program, Greenebaum Cancer Center, University of Maryland, Baltimore, Maryland 21201-1180
Tumor necrosis factor-related apoptosis-inducing-ligand (TRAIL/Apo-2 ligand) induces apoptosis in the majority of cancer cells without appreciable effect in normal cells. Here, we report the effects of TRAIL on apoptosis in several human breast cancer cell lines, primary memory epithelial cells, and immortalized nontransformed cell lines, and we examine whether chemotherapeutic agents augment TRAIL-induced cytotoxicity in breast cancer cells in vitro and in vivo. TRAIL induced apoptosis with different sensitivities, and the majority of cancer cell lines were resistant to TRAIL. The chemotherapeutic drugs (paclitaxel, vincristine, vinblastine, etoposide, camptothecin, and Adriamycin) induced death receptors (DRs) TRAIL receptor 1/DR4 and TRAIL receptor 2/DR5, and successive treatment with TRAIL resulted in apoptosis of both TRAIL-sensitive and -resistant cells. Actinomycin D sensitized TRAIL-resistant cells through up-regulation of caspases (caspase-3, -9, and -8). TRAIL induces apoptosis in Adriamycin-resistant MCF7 cells already expressing high levels of death receptors DR4 and DR5. The pretreatment of breast cancer cells with chemotherapeutic drugs followed by TRAIL reversed their resistance by triggering caspase-3, -9, and -8 activation. The sequential treatment of nude mice with chemotherapeutic drugs followed by TRAIL induced caspase-3 activity and apoptosis in xenografted tumors. Complete eradication of established tumors and survival of mice were achieved without detectable toxicity. Thus, the sequential administration of chemotherapeutic drugs followed by TRAIL may be used as a new therapeutic approach for cancer therapy.
This article has been cited by other articles:
|
|
 |
|
  T. Yoshida, Y. Zhang, L. A. Rivera Rosado, and B. Zhang Repeated Treatment with Subtoxic Doses of TRAIL Induces Resistance to Apoptosis through Its Death Receptors in MDA-MB-231 Breast Cancer Cells Mol. Cancer Res., November 1, 2009; 7(11): 1835 - 1844. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Shankar, R. Davis, K. P. Singh, R. Kurzrock, D. D. Ross, and R. K. Srivastava Suberoylanilide hydroxamic acid (Zolinza/vorinostat) sensitizes TRAIL-resistant breast cancer cells orthotopically implanted in BALB/c nude mice Mol. Cancer Ther., June 1, 2009; 8(6): 1596 - 1605. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Zhang and B. Zhang TRAIL Resistance of Breast Cancer Cells Is Associated with Constitutive Endocytosis of Death Receptors 4 and 5 Mol. Cancer Res., December 1, 2008; 6(12): 1861 - 1871. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Kato, A. Sadarangani, S. Lange, A. M. Delpiano, M. Vargas, J. Branes, J. Carvajal, S. Lipkowitz, G. I. Owen, and M. A. Cuello 2-Methoxyestradiol Mediates Apoptosis Through Caspase-Dependent and Independent Mechanisms in Ovarian Cancer Cells But Not in Normal Counterparts Reproductive Sciences, November 1, 2008; 15(9): 878 - 894. [Abstract] [PDF]
|
|
|
|
 |
|
 S. Shankar, S. Ganapathy, and R. K. Srivastava Sulforaphane Enhances the Therapeutic Potential of TRAIL in Prostate Cancer Orthotopic Model through Regulation of Apoptosis, Metastasis, and Angiogenesis Clin. Cancer Res., November 1, 2008; 14(21): 6855 - 6866. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Shankar, Q. Chen, S. Ganapathy, K. P. Singh, and R. K. Srivastava Diallyl trisulfide increases the effectiveness of TRAIL and inhibits prostate cancer growth in an orthotopic model: molecular mechanisms Mol. Cancer Ther., August 1, 2008; 7(8): 2328 - 2338. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Nagano, J. Y. Perentes, R. K. Jain, and Y. Boucher Cancer Cell Death Enhances the Penetration and Efficacy of Oncolytic Herpes Simplex Virus in Tumors Cancer Res., May 15, 2008; 68(10): 3795 - 3802. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Kim, J. Liao, M. L. Dowling, K. R. Voong, S. E. Parker, S. Wang, W. S. El-Deiry, and G. D. Kao TRAIL Inactivates the Mitotic Checkpoint and Potentiates Death Induced by Microtubule-Targeting Agents in Human Cancer Cells Cancer Res., May 1, 2008; 68(9): 3440 - 3449. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. G. Oliver, A. F. LoBuglio, K. R. Zinn, H. Kim, L. Nan, T. Zhou, W. Wang, and D. J. Buchsbaum Treatment of Human Colon Cancer Xenografts with TRA-8 Anti-death Receptor 5 Antibody Alone or in Combination with CPT-11 Clin. Cancer Res., April 1, 2008; 14(7): 2180 - 2189. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. H. Chen, C. C. Jiang, K. A. Kiejda, Y. F. Wang, R. F. Thorne, X. D. Zhang, and P. Hersey Thapsigargin sensitizes human melanoma cells to TRAIL-induced apoptosis by up-regulation of TRAIL-R2 through the unfolded protein response Carcinogenesis, November 1, 2007; 28(11): 2328 - 2336. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. C. Jiang, L. H. Chen, S. Gillespie, K. A. Kiejda, N. Mhaidat, Y. F. Wang, R. Thorne, X. D. Zhang, and P. Hersey Tunicamycin Sensitizes Human Melanoma Cells to Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand-Induced Apoptosis by Up-regulation of TRAIL-R2 via the Unfolded Protein Response Cancer Res., June 15, 2007; 67(12): 5880 - 5888. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Kim, T. R. Chaudhuri, D. J. Buchsbaum, D. Wang, and K. R. Zinn High-resolution single-photon emission computed tomography and X-ray computed tomography imaging of Tc-99m-labeled anti-DR5 antibody in breast tumor xenografts Mol. Cancer Ther., March 1, 2007; 6(3): 866 - 875. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Sasaki, N. Ohara, Q. Xu, J. Wang, D. A. DeManno, K. Chwalisz, S. Yoshida, and T. Maruo A Novel Selective Progesterone Receptor Modulator Asoprisnil Activates Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (TRAIL)-Mediated Signaling Pathway in Cultured Human Uterine Leiomyoma Cells in the Absence of Comparable Effects on Myometrial Cells J. Clin. Endocrinol. Metab., February 1, 2007; 92(2): 616 - 623. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. M. McCarthy, K. A. DiVito, M. Sznol, D. Kovacs, R. Halaban, A. J. Berger, K. T. Flaherty, R. L. Camp, R. Lazova, D. L. Rimm, et al. Expression of tumor necrosis factor-related apoptosis-inducing ligand receptors 1 and 2 in melanoma. Clin. Cancer Res., June 15, 2006; 12(12): 3856 - 3863. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. M. Thai, A. Labrinidis, S. Hay, V. Liapis, S. Bouralexis, K. Welldon, B. J. Coventry, D. M. Findlay, and A. Evdokiou Apo2l/Tumor necrosis factor-related apoptosis-inducing ligand prevents breast cancer-induced bone destruction in a mouse model. Cancer Res., May 15, 2006; 66(10): 5363 - 5370. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Basu, V. P. Castle, M. Bouziane, K. Bhalla, and S. Haldar Crosstalk between Extrinsic and Intrinsic Cell Death Pathways in Pancreatic Cancer: Synergistic Action of Estrogen Metabolite and Ligands of Death Receptor Family. Cancer Res., April 15, 2006; 66(8): 4309 - 4318. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Hasegawa, Y. Yamada, K. Komiyama, M. Hayashi, M. Ishibashi, T. Yoshida, T. Sakai, T. Koyano, T.-S. Kam, K. Murata, et al. Dihydroflavonol BB-1, an extract of natural plant Blumea balsamifera, abrogates TRAIL resistance in leukemia cells Blood, January 15, 2006; 107(2): 679 - 688. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. M. McCarthy, M. Sznol, K. A. DiVito, R. L. Camp, D. L. Rimm, and H. M. Kluger Evaluating the Expression and Prognostic Value of TRAIL-R1 and TRAIL-R2 in Breast Cancer Clin. Cancer Res., July 15, 2005; 11(14): 5188 - 5194. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Shetty, B. A. Graham, J. G. Brown, X. Hu, N. Vegh-Yarema, G. Harding, J. T. Paul, and S. B. Gibson Transcription Factor NF-{kappa}B Differentially Regulates Death Receptor 5 Expression Involving Histone Deacetylase 1 Mol. Cell. Biol., July 1, 2005; 25(13): 5404 - 5416. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Qanungo, M. Das, S. Haldar, and A. Basu Epigallocatechin-3-gallate induces mitochondrial membrane depolarization and caspase-dependent apoptosis in pancreatic cancer cells Carcinogenesis, May 1, 2005; 26(5): 958 - 967. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. C. Broaddus, T. B. Dansen, K. S. Abayasiriwardana, S. M. Wilson, A. J. Finch, L. B. Swigart, A. E. Hunt, and G. I. Evan Bid Mediates Apoptotic Synergy between Tumor Necrosis Factor-related Apoptosis-inducing Ligand (TRAIL) and DNA Damage J. Biol. Chem., April 1, 2005; 280(13): 12486 - 12493. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. S. Merchant, X. Yang, F. Melchionda, M. Romero, R. Klein, C. J. Thiele, M. Tsokos, H. U. Kontny, and C. L. Mackall Interferon {gamma} Enhances the Effectiveness of Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Receptor Agonists in a Xenograft Model of Ewing's Sarcoma Cancer Res., November 15, 2004; 64(22): 8349 - 8356. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
